ASCO: Endocrine Tx Noninferior for HR & #43;, HER2 & #8722; Breast Cancer

MONDAY, June 4, 2018 -- For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news